Xenetic Biosciences, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
NV
Business Address
945 CONCORD ST., FRAMINGHAM, MA, 01701
Mailing Address
945 CONCORD ST., FRAMINGHAM, MA, 01701
Phone
781-778-7720
Fiscal Year End
1231
EIN
452952962
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 13, 2026 | View on SEC |
| 10-K Annual financial report | March 12, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 12, 2026 | View on SEC |
| 8-K Current report of material events | January 9, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 4 Insider stock transaction report | January 5, 2026 | View on SEC |
| 8-K Current report of material events | December 11, 2025 | View on SEC |
| 8-K Current report of material events | November 13, 2025 | View on SEC |
Annual Reports
10-K
March 12, 2026
- Advancing lead DNase technology into Phase 1/2a clinical trials for pancreatic cancer and other solid tumors, targeting NETs to enhance immunotherapy.
- Proprietary PolyXen® platform offers drug delivery improvements and is actively seeking out-licensing and collaboration opportunities for upfront payments, milestones, and royalties.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.